On the other hand, the use of new IL-6 inhibitors such as clazakizumab, a monoclonal antibody with high affinity and specificity for IL-6, could be more promising for psoriatic arthritis (PsA) [57,64,65,66]. Here, IL6 is linked to psoriatic arthritis.